Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular Carcinoma
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
\- Background Hepatocellular carcinoma (HCC), is the fifth most common cancer worldwide and the third leading cause of cancer-related death. In most cases (about 80%), HCC develops in a cirrhotic liver - a condition where the liver has been damaged over time, leading to scarring. This makes treatment more challenging. This study will gather and analyze data from patients treated in real-world settings to: 1. Understand the effectiveness and safety of new treatment combinations (e.g., atezolizumab-bevacizumab and durvalumab-tremelimumab). Identify the best treatment sequences for patients with advanced liver cancer. 2. Discover clinical and laboratory markers that predict treatment responses, helping personalize care and optimize outcomes. By addressing these questions, this study will provide valuable information to healthcare providers and guide future treatment decisions for patients with liver cancer.
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
You may qualify if…
- ✓ Hepatocellular carcinoma not amenable to locoregional procedures
- ✓ Candidate to frontline systemic treatment with atezolizumab-bevacizumab or other immunotherapies
You may not qualify if…
- ✕ Concurrent treatment with other antineoplastic agents
- ✕ Other active neoplasia
Where it's recruiting
Modena
Source: ClinicalTrials.gov · NCT06806579 · last updated 2025-02-04